May 25, 2020

Tango Therapeutics – $60 Million

Date posted: 04/12/2020

Business location: Cambridge, MA. 

Amount Funded: $60 Million

Type: Series B

Lead Investor: Boxer Capital

Participating Investor(s):  Cormorant Asset Management, Casdin Capital

Note:  Investors in red are new investors to this company.

Total Funding to Date: $58 Million

Company Description: “Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of targeted therapies to people with cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer.”

What funding will be used for:  To advance lead program into IND-enabling studies

Further information (media):

Molly Rusert
Ten Bridge Communications
molly@tenbridgecommunications.com
(612) 232-2084

Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy. 

 

StartupsOne

StartupsOne features relevant, focused news on venture capital funding of technology oriented startup businesses based in North America.

View all posts by StartupsOne →